Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Bio Q3 Revenues Rise 6 Percent

NEW YORK – Interpace Biosciences reported Wednesday morning that its third quarter revenues rose 6 percent year over year.

For the three months ended Sept. 30, 2020 the Parsippany, New Jersey-based firm had total revenues of $8.2 million compared to $7.7 million a year ago, beating analysts' average expectations of $7.6 million.

Interpace also announced that it closed a $5 million bridge loan with existing equity investors Ampersand Capitol Partners and 1315 Capital Partners earlier this month. The firm concurrently terminated its credit facility with Silicon Valley Bank.

Subsequent to the end of the third quarter, Interpace received notice from the Nasdaq that it was in violation of a Nasdaq Listing rule due to the delay in filing its Form 10-Q for the quarter ended Sept. 30.

Interpace posted a net loss of $6.2 million, or $1.54 per share, compared to a net loss of $7.4 million, or $1.97 per share a year ago. The firm beat the consensus Wall Street estimate of a net loss of $1.92 per share.

The company's R&D expenses fell 11 percent to $763,000 from $857,000 in the year-ago period. It's sales, marketing, general, and administrative expenses fell 1 percent to $7.2 million from $7.3 million.

Interpace finished the quarter with $5.3 million in cash and cash equivalents.

For the fourth quarter, the company estimated revenues to be between $9.0 and $10.0 million.

In early morning trading on the Nasdaq, Interpace's shares were down about 11 percent at $4.06.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.